- Home
- HCWC vs KPRX Comparison
HCWC vs KPRX Comparison
Compare HCWC & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HCWC
- KPRX
- Stock Information
- Founded
- HCWC N/A
- KPRX 1998
- Country
- HCWC
- KPRX United States
- Employees
- HCWC N/A
- KPRX N/A
- Industry
- HCWC
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- HCWC
- KPRX Health Care
- Exchange
- HCWC NYSE
- KPRX Nasdaq
- Market Cap
- HCWC 11.8M
- KPRX 10.0M
- IPO Year
- HCWC N/A
- KPRX N/A
- Fundamental
- Price
- HCWC $0.83
- KPRX $3.26
- Analyst Decision
- HCWC
- KPRX Strong Buy
- Analyst Count
- HCWC 0
- KPRX 1
- Target Price
- HCWC N/A
- KPRX $10.00
- AVG Volume (30 Days)
- HCWC N/A
- KPRX 34.9K
- Earning Date
- HCWC N/A
- KPRX 11-08-2024
- Dividend Yield
- HCWC N/A
- KPRX N/A
- EPS Growth
- HCWC N/A
- KPRX N/A
- EPS
- HCWC N/A
- KPRX 1.69
- Revenue
- HCWC N/A
- KPRX $16,020,000.00
- Revenue This Year
- HCWC N/A
- KPRX N/A
- Revenue Next Year
- HCWC N/A
- KPRX N/A
- P/E Ratio
- HCWC N/A
- KPRX $2.04
- Revenue Growth
- HCWC N/A
- KPRX N/A
- 52 Week Low
- HCWC N/A
- KPRX $3.00
- 52 Week High
- HCWC N/A
- KPRX $8.98
- Technical
- Relative Strength Index (RSI)
- HCWC N/A
- KPRX 43.44
- Support Level
- HCWC N/A
- KPRX $3.30
- Resistance Level
- HCWC N/A
- KPRX $4.04
- Average True Range (ATR)
- HCWC 0.00
- KPRX 0.28
- MACD
- HCWC 0.00
- KPRX -0.01
- Stochastic Oscillator
- HCWC 0.00
- KPRX 7.14
About HCWC HEALTHY CHOICE WELLNESS CORP
Healthy Choice Wellness Corp is a company engaged in providing consumers with healthier daily choices with respect to nutrition and other lifestyle alternatives. The company has one reportable segment which is natural and organic retail stores.
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.